What Saniona does

Saniona AB (publ) is a clinical-stage biopharmaceutical company founded in 2011 and listed on Nasdaq Stockholm Small Cap under the ticker SANION, with operating headquarters in Glostrup, Denmark. The company is a pioneer in ion channel research and operates a proprietary drug discovery platform that has generated a library of more than 20,000 proprietary small molecules targeting various ion channels. Saniona focuses on neurological, psychiatric, and rare disease indications with high unmet medical need, including severe pediatric epilepsies (SAN2668, SAN2219, SAN711, SAN2355), major depressive disorder (SAN2465), inflammatory bowel disease and fibrotic diseases (SAN903), and rare obesity disorders (Tesomet for hypothalamic obesity and Prader-Willi syndrome, tesofensin partnered with Medix for Mexico/Argentina).

Saniona's business model is a capital-efficient partnered development model. The company discovers and develops pre-clinical and early-clinical candidates internally using its ion channel platform, then out-licenses global or regional development and commercialization rights to pharmaceutical partners who fund further clinical trials, regulatory submissions, and commercialization. Revenue is generated from licensing upfront payments, development and regulatory milestone payments, and royalties, supplemented by non-dilutive funding from research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Notable commercial partnerships include Jazz Pharmaceuticals (global rights to SAN2355, August 2025 deal potentially worth over $1 billion), Acadia Pharmaceuticals (global rights to ACP-711 for essential tremor), and Medix (tesofensin for obesity in Mexico and Argentina, with a positive COFEPRIS opinion in February 2023). The company operates with 11-50 employees and has no approved products on the market.

Name

Saniona

Legal name

Saniona AB (publ)

Website

https://saniona.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Saniona is a clinical-stage biopharmaceutical company pioneering ion channel drug discovery, with a proprietary library of 20,000+ molecules targeting neurological, psychiatric, and rare diseases. It licenses pipeline assets to pharmaceutical partners including Jazz, Acadia, and Medix for global development and commercialization.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals (ion channel therapeutics)

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Ion channel drug discovery
• Clinical-stage biopharmaceuticals
• Neurological disease therapeutics
• Rare disease drug development
• Epilepsy treatment pipeline

Headquarters

HQ city

Ballerup

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Licensing and milestone payments: Saniona generates revenue through upfront payments, development milestones, regulatory milestones, and commercial royalties from licensing agreements with pharmaceutical partners who acquire global rights to its pipeline candidates (e.g., Jazz Pharmaceuticals for SAN2355, Acadia Pharmaceuticals for ACP-711, Medix for tesofensin in Mexico/Argentina). The Jazz deal for SAN2355 is described as potentially over one billion dollars.
2. Research and development partnerships: Saniona participates in research collaborations with pharmaceutical companies (Boehringer Ingelheim, AstronauTx, Cephagenix) that provide funding for early-stage discovery and platform validation. These partnerships contribute non-dilutive capital.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Saniona is a clinical-stage biopharmaceutical company that discovers and develops novel treatments for neurological, psychiatric, metabolic, and inflammatory diseases by leveraging a proprietary ion channel drug discovery platform with a library of more than 20,000 proprietary molecules. Its pipeline includes clinical and preclinical candidates for epilepsy (SAN2668, SAN2219, SAN711, SAN2355), depression (SAN2465), inflammatory bowel disease (SAN903), and obesity-related rare disorders (Tesofensin, Tesomet), with most late-stage and commercial rights out-licensed to pharmaceutical partners.

Product overview

Saniona is a clinical-stage biopharmaceutical company and pioneer in ion channel research, advancing multiple potential new medicines through clinical trials. The company's product portfolio centers on its proprietary ion channel drug discovery platform, which has generated a library of more than 20,000 proprietary molecules targeting various ion channels. Saniona's internal epilepsy pipeline includes SAN2668 (leading clinical candidate for severe pediatric epilepsies, moving toward Phase 1 in 2026), SAN711 (ready for Phase 2 for absences), and SAN2219 (preclinical for acute repetitive epileptic seizures). Beyond epilepsy, the company has partnered programs including Tesofensin (partnered with Medix for obesity) and Tesomet (for hypothalamic obesity and Prader-Willi syndrome), as well as SAN903 (for inflammatory bowel disease) and SAN2465 (for severe depression). SAN2355 was licensed to Jazz Pharmaceuticals for global development in epilepsy.

Differentiator

Problem solved

Functional benefit

Products and services

• SAN2668 Subtype-selective GABAA positive allosteric modulator (PAM) designed with selective pharmacology targeting relevant GABAA receptor subtypes involved in seizure control; Saniona's leading clinical candidate for treatment of severe pediatric epilepsies including developmental and epileptic encephalopathies (DEEs).
• SAN2219 Subtype-selective positive allosteric modulator of GABAA alpha2, alpha3, and alpha5 receptors designed to induce robust anti-seizure effects for acute repetitive epileptic seizures by broadly dampening excessive neuronal activation without the sedating effects of non-selective benzodiazepines.
• SAN711 Saniona's most advanced patented ion channel modulator being developed for the treatment of absence seizures (a form of epileptic seizures); Phase 1 study on healthy volunteers reported positive results in July 2022 and the candidate is ready for Phase 2 clinical studies.
• SAN2355 Preclinical Kv7.2/Kv7.3 ion channel activator being investigated for epilepsy and other potential indications; development and commercialization rights licensed exclusively worldwide to Jazz Pharmaceuticals following an August 2025 global licensing agreement.
• Tesofensin Unique triple monoamine reuptake inhibitor modulating dopamine, serotonin, and norepinephrine to regulate appetite, food-seeking behavior, and metabolism; partnered with Medix for obesity treatment in Mexico and Argentina where a marketing authorization application is under review, demonstrated approximately 10% or greater weight loss at 24 weeks at 0.50 mg/day in Phase 2 studies.
• Tesomet Fixed-dose combination of tesofensine (triple monoamine reuptake inhibitor) and metoprolol (selective beta-1 blocker) being developed for hypothalamic obesity and Prader-Willi syndrome; Phase 2b studies voluntarily paused for financial reasons unrelated to safety or efficacy.
• SAN903 Potential first-in-class inhibitor of the calcium-activated potassium channel KCa3.1 for inflammatory and fibrotic diseases; lead indication is inflammatory bowel disease (IBD) and the candidate is ready for Phase 1 clinical trials.
• SAN2465 Highly potent and selective negative allosteric modulator (NAM) of GABAA alpha5-containing receptors in development as a rapid-acting antidepressant for major depressive disorder with a pharmacological profile distinct from conventional antidepressants, NMDA antagonists, and psychedelic investigational drugs; moving toward Phase 1 studies in 2026.
• Ion Channel Drug Discovery Platform Proprietary drug discovery engine generating a library of more than 20,000 proprietary molecules targeting various ion channels, used to design highly specific ion channel modulators and to support both internal pipeline development and partnered research collaborations with pharmaceutical companies.

Quantifiable outcome

• Tesofensin demonstrated approximately 10% or greater weight loss at 24 weeks at the expected recommended dose of 0.50 mg/day in Phase 2 clinical studies, comparable to leading GLP-1 analogs. Unlike GLP-1 analogs, tesofensin is provided as a tablet without requiring titration.
• +2 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• Jazz PharmaceuticalscoreStrategic or Co-development Partner · 21 August 2025Jazz Pharmaceuticals and Saniona entered into a global license agreement granting Jazz exclusive worldwide rights to develop SAN2355, a pre-clinical Kv7.2/Kv7.3 activator being investigated for epilepsy and other potential indications. Jazz will lead and fund all further development, regulatory submissions, and global commercialization activities under the potentially over billion-dollar deal. Saniona's shares surged 58% to 12.92 kroner following the announcement.
• Acadia PharmaceuticalscoreStrategic or Co-development PartnerAcadia Pharmaceuticals holds global rights to ACP-711 (a Saniona-derived asset) for essential tremor. This partnership represents an additional validation of Saniona's ion channel drug discovery platform.
• MedixcoreStrategic or Co-development PartnerMedix holds rights to tesofensin for obesity in Mexico and Argentina. Saniona's collaboration partner Medix completed a Phase 3 program for tesofensin in obesity and submitted a New Drug Application to COFEPRIS (Mexican regulatory authority). In February 2023, COFEPRIS technical committee issued a positive opinion on tesofensin as a treatment for obesity.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• UCB: UCB is a large global biopharmaceutical company with a major franchise in epilepsy (e.g., Vimpat, Briviact, Keppra) and a growing presence in rare diseases through its acquisition of Zogenix. Its deep epilepsy portfolio makes it a relevant broad incumbent comparable to Saniona's CNS pipeline.
• Jazz Pharmaceuticals: Jazz Pharmaceuticals is a large global biopharmaceutical company with deep CNS and epilepsy franchises (e.g., Epidiolex, Xywav). It is Saniona's licensee for SAN2355 and represents the type of established CNS player Saniona's partnered model is designed to access for late-stage development.
• Acadia Pharmaceuticals: Acadia Pharmaceuticals is a CNS-focused biopharmaceutical company with an approved product for Parkinson's disease psychosis and a pipeline in essential tremor and other CNS indications. It licenses ACP-711 from Saniona for essential tremor, providing direct platform validation and representing a broader CNS incumbent comparable.

Direct peers

• Axsome Therapeutics: Axsome Therapeutics is a CNS-focused biopharmaceutical company with approved products for major depressive disorder and migraine. Its rapid-acting antidepressant franchise and CNS pipeline positioning make it a direct comparable to Saniona's SAN2465 and broader CNS strategy.
• Marinus Pharmaceuticals: Marinus Pharmaceuticals is a clinical-stage company developing GABAA receptor modulators for seizure disorders including status epilepticus and rare epilepsies. Its mechanism of action and patient focus on rare pediatric epilepsies directly overlaps with Saniona's epilepsy franchise.
• Xenon Pharmaceuticals: Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ion channel drug discovery for neurological disorders, including epilepsy. Its pipeline of Kv7 and other ion channel modulators directly parallels Saniona's ion channel platform, making it the closest comparable in mechanism and therapeutic focus.
• Sage Therapeutics: Sage Therapeutics is a CNS-focused biopharmaceutical company with approved products in depression (Zurzuvae) and historically in epilepsy. Its GABAA receptor modulator franchise directly competes with Saniona's SAN2219 and SAN2668 programs in CNS indications.
• Praxis Precision Medicines: Praxis Precision Medicines is a clinical-stage company developing therapies for CNS disorders including epilepsy and rare pediatric neurological conditions. Its focus on treatment-resistant epilepsies and rare CNS indications directly overlaps Saniona's SAN2668 and SAN2219 programs.

Emerging players

• Longboard Pharmaceuticals: Longboard Pharmaceuticals is a clinical-stage company developing CNS therapies, including a 5-HT2C receptor agonist for rare epilepsies. Its smaller scale and CNS focus make it an emerging comparable to Saniona's pediatric epilepsy strategy.
• Engage Therapeutics: Engage Therapeutics (acquired by UCB in 2020) developed a Staccato alprazolam therapy for acute repetitive seizures — directly overlapping with Saniona's SAN2219 program. As a recently validated target in acute seizure treatment, it represents an emerging comparable for Saniona's acute repetitive seizure strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/saniona_ab
• YouTubeyoutube.com/channel/UCP__Uw9bOQrAHqNocsfQhRQ/featured
• LinkedInlinkedin.com/company/saniona

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Saniona